PriceTargets.com logo

FSD Pharma - HUGE Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.09 As of 08/14/2024 05:00 PM ET
▼ -0.0101 (-10.10%)
Get New FSD Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HUGE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HUGE

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for FSD Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.09.

This chart shows the closing price for HUGE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in FSD Pharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/19/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/15/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/14/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/13/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/7/2024Singular ResearchReiterated RatingBuy-Venture
8/20/2020Brookline Capital ManagementReiterated RatingBuy
8/20/2020Brookline Capital ManagementInitiated CoverageBuy$11.00
(Data available from 11/13/2019 forward)

News Sentiment Rating

0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/17/2024
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
5/17/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/16/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/15/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/14/2024
  • 0 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/14/2024
  • 2 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/13/2024

Current Sentiment

  • 2 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

FSD Pharma logo
FSD Pharma Inc., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. FSD Pharma Inc. is headquartered in Toronto, Canada.
Read More

Today's Range

Now: $0.09
Low: $0.09
High: $0.10

50 Day Range

MA: $0.11
Low: $0.08
High: $0.20

52 Week Range

Now: $0.09
Low: $0.07
High: $1.68

Volume

22,325,600 shs

Average Volume

10,137,857 shs

Market Capitalization

$3.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Frequently Asked Questions

What sell-side analysts currently cover shares of FSD Pharma?

The following Wall Street research analysts have issued reports on FSD Pharma in the last year: Singular Research.
View the latest analyst ratings for HUGE.

What is the current price target for FSD Pharma?

0 Wall Street analysts have set twelve-month price targets for FSD Pharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for FSD Pharma in the next year.
View the latest price targets for HUGE.

What is the current consensus analyst rating for FSD Pharma?

FSD Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for HUGE.

What other companies compete with FSD Pharma?

Other companies that are similar to FSD Pharma include Alvotech, Biofrontera, Clever Leaves, Cyclo Therapeutics and Procaps Group. Learn More about companies similar to FSD Pharma.

How do I contact FSD Pharma's investor relations team?

FSD Pharma's physical mailing address is 520 WILLIAM STREET, COBOURG A6, K9A 3A5. The company's listed phone number is (416) 854-8884 and its investor relations email address is [email protected]. The official website for FSD Pharma is fsdpharma.com. Learn More about contacing FSD Pharma investor relations.